Generate Biomedicines (NASDAQ:GENB) Shares Down 9.7% – Time to Sell?

by · The Cerbat Gem

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) shares traded down 9.7% during trading on Monday. The stock traded as low as $11.02 and last traded at $10.9040. Approximately 255,397 shares changed hands during trading, a decline of 70% from the average daily volume of 861,277 shares. The stock had previously closed at $12.07.

Analyst Upgrades and Downgrades

GENB has been the subject of several recent research reports. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. HC Wainwright reaffirmed a “buy” rating on shares of Generate Biomedicines in a research note on Friday, October 30th. Finally, Weiss Ratings raised shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Generate Biomedicines currently has an average rating of “Moderate Buy” and an average target price of $26.40.

Get Our Latest Stock Report on Generate Biomedicines

Generate Biomedicines Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.01 and a current ratio of 5.01. The stock’s 50 day simple moving average is $14.35 and its two-hundred day simple moving average is $14.11. The firm has a market capitalization of $1.37 billion and a PE ratio of -6.71.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.18). The company had revenue of $4.22 million for the quarter. Generate Biomedicines had a negative return on equity of 151.21% and a negative net margin of 1,289.97%. On average, sell-side analysts forecast that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Generate Biomedicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new stake in Generate Biomedicines in the 2nd quarter valued at $196,000. AXQ Capital LP purchased a new position in shares of Generate Biomedicines during the 2nd quarter worth $218,000. Summa Corp. acquired a new position in shares of Generate Biomedicines during the 3rd quarter valued at about $250,000. Magnus Financial Group LLC boosted its position in shares of Generate Biomedicines by 39.4% during the 3rd quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock valued at $327,000 after acquiring an additional 6,150 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Generate Biomedicines in the second quarter valued at about $530,000.

About Generate Biomedicines

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Featured Stories